BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
IVDs on the rise
Radiopharmaceuticals
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, September 24, 2023
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Novel anti-IL-17A inhibitor shows similar efficacy to biological therapies in IL-17-driven disorders
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immune
Novel anti-IL-17A inhibitor shows similar efficacy to biological therapies in IL-17-driven disorders
Sep. 1, 2023
No Comments
Interleukin-17A (IL-17A) is a pro-inflammatory cytokine involved in the pathogenesis of inflammatory, immune-mediated diseases such as psoriasis, psoriatic arthritis and others.
BioWorld Science
Conferences
Immune